Shanxi Zhendong Pharmaceutical (300158) - Total Assets

Latest as of September 2025: CN¥4.51 Billion CNY ≈ $660.15 Million USD

Based on the latest financial reports, Shanxi Zhendong Pharmaceutical (300158) holds total assets worth CN¥4.51 Billion CNY (≈ $660.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Shanxi Zhendong Pharmaceutical's book value for net asset value and shareholders' equity analysis.

Shanxi Zhendong Pharmaceutical - Total Assets Trend (2007–2024)

This chart illustrates how Shanxi Zhendong Pharmaceutical's total assets have evolved over time, based on quarterly financial data.

Shanxi Zhendong Pharmaceutical - Asset Composition Analysis

Current Asset Composition (December 2024)

Shanxi Zhendong Pharmaceutical's total assets of CN¥4.51 Billion consist of 64.5% current assets and 35.5% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 11.7%
Accounts Receivable CN¥775.81 Million 15.6%
Inventory CN¥775.98 Million 15.6%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥371.90 Million 7.5%
Goodwill CN¥15.50 Million 0.3%

Asset Composition Trend (2007–2024)

This chart illustrates how Shanxi Zhendong Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300158 company net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Shanxi Zhendong Pharmaceutical's current assets represent 64.5% of total assets in 2024, an increase from 46.0% in 2007.
  • Cash Position: Cash and equivalents constituted 11.7% of total assets in 2024, up from 7.0% in 2007.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 15.0% in 2007.
  • Asset Diversification: The largest asset category is inventory at 15.6% of total assets.

Shanxi Zhendong Pharmaceutical Competitors by Total Assets

Key competitors of Shanxi Zhendong Pharmaceutical based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Shanxi Zhendong Pharmaceutical - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.14 5.40 2.24
Quick Ratio 2.35 3.91 1.75
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥1.80 Billion CN¥3.22 Billion CN¥2.11 Billion

Shanxi Zhendong Pharmaceutical - Advanced Valuation Insights

This section examines the relationship between Shanxi Zhendong Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.64
Latest Market Cap to Assets Ratio 0.17
Asset Growth Rate (YoY) -19.4%
Total Assets CN¥4.98 Billion
Market Capitalization $830.57 Million USD

Valuation Analysis

Below Book Valuation: The market values Shanxi Zhendong Pharmaceutical's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Shanxi Zhendong Pharmaceutical's assets decreased by 19.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Shanxi Zhendong Pharmaceutical (2007–2024)

The table below shows the annual total assets of Shanxi Zhendong Pharmaceutical from 2007 to 2024.

Year Total Assets Change
2024-12-31 CN¥4.98 Billion
≈ $729.13 Million
-19.38%
2023-12-31 CN¥6.18 Billion
≈ $904.40 Million
-5.65%
2022-12-31 CN¥6.55 Billion
≈ $958.60 Million
-35.10%
2021-12-31 CN¥10.09 Billion
≈ $1.48 Billion
+32.75%
2020-12-31 CN¥7.60 Billion
≈ $1.11 Billion
+9.95%
2019-12-31 CN¥6.92 Billion
≈ $1.01 Billion
-4.12%
2018-12-31 CN¥7.21 Billion
≈ $1.06 Billion
-5.27%
2017-12-31 CN¥7.61 Billion
≈ $1.11 Billion
+10.75%
2016-12-31 CN¥6.87 Billion
≈ $1.01 Billion
+68.89%
2015-12-31 CN¥4.07 Billion
≈ $595.64 Million
+42.41%
2014-12-31 CN¥2.86 Billion
≈ $418.26 Million
+2.20%
2013-12-31 CN¥2.80 Billion
≈ $409.27 Million
+8.25%
2012-12-31 CN¥2.58 Billion
≈ $378.09 Million
+14.54%
2011-12-31 CN¥2.26 Billion
≈ $330.10 Million
+3.93%
2010-12-31 CN¥2.17 Billion
≈ $317.61 Million
+237.46%
2009-12-31 CN¥643.18 Million
≈ $94.12 Million
+29.49%
2008-12-31 CN¥496.69 Million
≈ $72.68 Million
+6.43%
2007-12-31 CN¥466.70 Million
≈ $68.29 Million
--

About Shanxi Zhendong Pharmaceutical

SHE:300158 China Drug Manufacturers - Specialty & Generic
Market Cap
$830.57 Million
CN¥5.68 Billion CNY
Market Cap Rank
#9965 Global
#2831 in China
Share Price
CN¥5.72
Change (1 day)
-0.35%
52-Week Range
CN¥3.88 - CN¥9.45
All Time High
CN¥12.00
About

Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sales of pharmaceutical drugs in China. It offers drugs for various fields, including tumors, dermatology, digestion, urology, and cardio-cerebral drugs. The company also provides Chinese herbal medicines. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is b… Read more